TissueGen announced a marketing partnership with Biomedical Structures (BMS) in 2013. BMS, as a recognized world leader in medical textiles, can utilize TissueGen’s drug-loaded fiber platform to develop biomedical textile structures designed for drug delivery within the body. Because TissueGen’s novel technology enables engineering of devices with both pharmaceutical composition and mechanical properties such as size, shape, and porosity specific to each application, a single structure can satisfy both physical and pharmaceutical performance requirements.
TissueGenInc., developer of a groundbreaking biodegradable fiber format for drug delivery, had a significant year in 2013 marked by strengthened #
The company participated alongside BMS at four leading industry tradeshows, including MD&M West, MD&M East, BIOMEDevice Boston and AMI's Medical Grade Polymers 2013 where they presented a joint session entitled “Medical Fabrics & Drug-Loaded Fibers: New Frontiers in Material Selection.” TissueGen also continued to build upon its intellectual property portfolio in 2013, including new patents and patents pending.
TissueGenInc., developer of a groundbreaking biodegradable fiber format for drug delivery, had a significant year in 2013 marked by strengthened #
“We are well-positioned for continued growth and success in the new year as we diligently focus on developing fibers for an expanding field of medical applications,” added Knowles.
TissueGenInc., developer of a groundbreaking biodegradable fiber format for drug delivery, had a significant year in 2013 marked by strengthened #
About TissueGen
TissueGenInc. has more than four decades of cumulative experience in extruding biodegradable polymer fibers with broad drug delivery capabilities. TissueGen offers the medical market a portfolio of issued patents on unique drug delivery technology with the capability to incorporate and elute a broad range of biologically derived therapeutics and standard pharmaceuticals in hydrophobic, biodegradable polymeric fibers or tubes for sustained therapeutic release.
TissueGen